Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIK Cells and S-1 in Advanced Pancreatic Cancer
NCT03002831Phase 2Terminated
- Sponsor
- Henan Cancer Hospital
- Start
- Nov 2016
- Primary completion
- Oct 2019
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of unmodified CIK in pancreatic cancer (PC), sponsored by Henan Cancer Hospital. Primary endpoint: Overall Survival at 36 months. Started Nov 2016; status: terminated.
02
Drugs
unmodified CIK
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03002831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002831.